179 results
8-K
EX-99.2
LUMO
Lumos Pharma Inc
5 Jun 24
Lumos Pharma Announces New Analyses of Phase 2
4:09pm
and attractive safety profile to date in 1,300 subjects studied Investment Thesis Oral therapeutic candidate targeting $4.7 billion growth-disorder … ➢ Consistent PD effect over 24 hours* ➢ MOA avoids risk of IGF-1 excursions ➢ Favorable investigational safety profile with1,300 patients treated
8-K
EX-99.1
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
endocrine feedback loop.
◦Investigational safety profile continues to be favorable.
Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Presented … compared to a non-inferiority study, that the investigational safety profile continues to be favorable, that cash on hand is expected to support
8-K
EX-99.2
LUMO
Lumos Pharma Inc
15 May 24
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
9:57am
sustained growth on LUM-201 o Favorable investigational safety profile to date OraGrowtH210 and OraGrowtH212 Phase 2 Clinical Trials* * Topline data … for up to 3 yearsPlacebo control 6 months N ~50 Cross to 1.6 g/ g/ ay 1 6 s LTSE = Long-term Safety Extension Cross-over from placebo to LUM-201
8-K
EX-99.1
LUMO
Lumos Pharma Inc
18 Apr 24
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
4:53pm
Growth Hormone Deficiency (PGHD) with a 1.6mg/kg/day Dose and a Promising Investigational Safety Record, Andrew Dauber, MD, et al, to be presented
8-K
EX-99.1
vkh4efao4vq5cgpr
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.2
ljl1r i8080b3
7 Mar 24
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
4:44pm
8-K
EX-99.1
lglunxpgxxc72
15 Nov 23
Other Events
4:38pm
8-K
EX-99.1
afia2rlt 0jap
7 Nov 23
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
4:42pm
8-K
EX-99.2
dplmuffb4myggamwlgg
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.1
ufljq6q7r6kow
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
8-K
EX-99.2
z6s6j
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.1
ylpp1vdnnukodge
9 Aug 23
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
4:36pm
8-K
EX-99.1
x23ui
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.2
y9zu09 9z7
21 Jun 23
Lumos to Highlight New LUM-201 Data and Analysis Presented
5:10pm
8-K
EX-99.1
am9 3e7lzbogia
8 May 23
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at
4:01pm